StockNews.AISignal intelligence
PepGen Inc. · NASDAQ · Healthcare
Browse public PEPG signals with their source context and measured market impact. Open any signal for its permanent analysis page.
PepGen announced pivotal results from its FREEDOM2 clinical trials are expected in early to mid-2026, reinforcing the potential of its drug PGN-EDODM1 for DM1 treatment. With a strong cash position to fund operations until late 2027, investors should watch upcoming data from the MDA conference closely, despite facing a partial FDA clinical hold.
View signal analysisPepGen shares surged 122.18% to $5.91 amid high trading volume. FREEDOM-DM1 trial shows 53.7% splicing correction at 15 mg/kg dose. All patients at 15 mg/kg showed improved treatment response. Upcoming results from FREEDOM2-DM1 MAD expected in Q1 2026. Company raised $100 million through a share offering at $3.20.
View signal analysisPepGen discontinued PGN-EDO51 for Duchenne muscular dystrophy due to unsatisfactory results. Favorable safety profile observed, but dystrophin levels were inadequate. Focus will shift to advancing DM1 program with ongoing Phase 2 clinical trials. Upcoming data expected from FREEDOM-DM1 and FREEDOM2-DM1 studies in 2025 and 2026. PEPG stock fell 6.69% following the announcement.
View signal analysisPepGen halts DMD therapy development after failed mid-stage study results.
View signal analysisPepGen temporarily pauses Phase 2 study to evaluate previous cohort results. Data from the 10 mg/kg cohort expected in Q3 2025. No new safety issues reported since January 2025 update. Focus shifts towards completing CONNECT1 and advancing FREEDOM studies. PEPG stock down 21% at $2.22 following announcement.
View signal analysis